Page 2 - Glenmark

Glenmark gets US health regulator nod for generic breast cancer injection

The product is a generic version of AstraZeneca Pharmaceuticals LP's Faslodex Injection in the same strength, the company said

Glenmark plans to divest non-core global assets to reduce debt by Rs 800 cr

Apart from rationalising costs, the company is also aiming to divest some of its non-core global assets as well as bring in a minority investor in to Glenmark Life Sciences

Top stock picks by Anand Rathi:Buy Kansai Nerolac, Glenmark, United Spirits

Nifty outlook and top trading ideas by Jay Anand Thakkar, CMT - Assistant Vice President - Equity Research, Anand Rathi Shares and Stock Brokers.

Glenmark Q3 net up 11% to Rs 116 crore on robust sales in India, US, Europe

Glenmark's consolidated revenue stood at Rs 2,555.04 crore during the October-December 2018 period from Rs 2,203.66 crore in the year-ago period

Glenmark inks pact with South Korea's Yuhan Corp to commercialise Ryaltris

Ryaltris is indicated for treatment of symptoms associated with seasonal allergic rhinitis (SAR) in patients over 12 years of age

Glenmark gets US FDA approval for tablets used to treat multiple sclerosis

The approved product is generic version of Sanofi-Aventis US' Aubagio

Glenmark to launch phase 1 trial in solid tumors for anti-myeloma drug

Glenmark Pharma said the decision to launch clinical trial is driven by recent findings derived from a non-interventional human study

Glenmark forms JV with True North for pain management, orthopaedic business

The business is valued at Rs 6.35 bn and Glenmark will continue to hold a stake in the new company

Out-licensing novel molecules key to Glenmark's debt reduction plan

The partner is likely to have the rights for the drug in the US, the EU and Japan markets and help with the approvals from the regulators in these countries

New products, over-the-counter business to fuel Glenmark's India growth

With growth of 8.6 per cent in the year ended March, Glenmark was the third-fastest among top 20 pharmaceutical companies, behind Lupin and Sanofi

Glenmark: Risk-reward turning favourable even as stocks hit 52-week low

Businesses in other geographies can drive growth, US challenges remain

US FDA issues adverse observations on Glenmark plant

The firm makes dermatology products including ointment and contributes around 10% of its US sales

Glenmark gets USFDA nod for Aprepitant capsules; cancer patients to benefit

Glenmark Pharmaceuticals today said its US-based arm has received final approval from the US FDA for Aprepitant capsules, used for preventing nausea caused by cancer chemotherapy. Glenmark Pharmaceuticals Inc, USA, has received final approval by the United States Food & Drug Administration (USFDA) for Aprepitant capsules USP, 40 mg, 80 mg, and 125 mg, the company said in a regulatory filing. The tablets are generic versions of Merck Sharp & Dohme Corporation's Emend capsules, it added. According to IMS health sales data for the 12 months ended August, Emend Capsules, 40 mg, 80 mg, and 125 mg achieved annual sales of around USD 64.9 million, Glenmark said. The company's current portfolio consists of 127 products authorised for distribution in the US marketplace and 60 abbreviated new drug applications (ANDAs) which are pending approval with the USFDA, it added. Shares of Glenmark Pharmaceuticals rose by 0.63 per cent to Rs 607 in morning trade on BSE.

Glenmark gets USFDA nod for generic skin ointment

The Mumbai-based firm's product is the generic version of Perrigo New York Inc's Desonide Ointment

Glenmark awaiting fresh triggers

Large product approvals, deals can drive growth, help pare debt

Glenmark shares plunge 16% on Q4 disappointment

The company reported lower than expected profit, guides for 12-15 sales growth in FY18

After disappointing Q4, Glenmark gives a guidance of 15% revenue growth

Says it saw lower than estimated sales for its top selling anti-cholesterol drug Zetia

Glenmark plans new launches in US, receives FDA nod for anticoagulant drug

Pradaxa is Glenmark's fourth product approval in the US from January till date

Glenmark, Evestra enter pact for generic contraceptive product

Drug firm Glenmark Pharmaceuticals has joined hands with Evestra Inc to develop and market a generic version of Merck & Co's contraceptive product. "Glenmark Pharmaceuticals Inc USA and Evestra Inc have completed a strategic development, licence and commercialisation agreement to develop and market a generic version of Merck & Co's NuvaRing product -- etonogestrel and ethinyl estradiol vaginal ring...," Glenmark Pharmaceuticals said in a statement. Development on the vaginal ring product is currently under way and the two companies expect to file an abbreviated new drug application (ANDA) in fiscal 2019, it added. As per the agreement, Evestra will develop this product exclusively for Glenmark for the US market and will receive certain milestone payments during various stages of its development, including royalties on net sales, Glenmark said. "The partnership with Evestra... Expands our portfolio into a leading non-daily contraceptive option prescribed for ..

Glenmark: Street awaiting fresh triggers

New approvals to launch drugs in US, rebound in growth, reduction in debt are key for upgrades